Protection by design

MEVOX combines in-house expertise with world class partnerships in antigen design and vaccine development. We leverage this cutting-edge vaccine innovation and translational expertise to bring established vaccines into the 21st century and address significant unmet needs.
Explore more

MEVOX

MEVOX brings vaccinology into the 21st century. We translate cutting-edge molecular characterization, design and engineering into conformationally precise and optimized protein vaccines. These induce 10-100 times higher neutralising antibody levels than existing vaccines, also showing sterilizing and durable immunity. We embed this scientific excellence in partnerships with world leaders on our target diseases with antigen design and translation. Our goal is global health impact through protection by design.

Discover our team

Board

Ken Kelley, Stephanie Monaghan O’Brien and Guillaume Stewart-Jones are part of the board.

Stephanie O’brien

Board
unnamed (52)

Guillaume Stewart-Jones

CEO/CSO
Sans titre

Ken Kelley

Chair
ken kelly
Discover more

and our investors

Our Values

Vaccine Architects Engineering
Protection by design
Cutting-edge-science-MEVOX-small

Cutting Edge Science

We apply atomic level antigen characterization, structure-based design and engineering to optimize immunogenicity, safety, producibility and access.
MEVOX - Synergy - You got it

Synergy

We partner with world class expertise and synergize the best both internally and externally.
MEVOX - Equitable Access

Equitable Access

We minimize barriers to access, whether they be stability, price, or scale.
Mevox Value Impact

Impact

We want to unleash human potential by removing the burden of infectious disease.
Love and energy at Mevox

Energy

What’s not energizing about making lives better, working with great people and great science?

Contact Us